Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma

Study:

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma

Rationale:

n/a

Purpose:

This Phase II, multicenter, randomized, double-blind, placebo-controlled trial is designed to estimate the efficacy and characterize the safety of bevacizumab when combined with carboplatin + paclitaxel chemotherapy compared with the carboplatin + paclitaxel chemotherapy alone in patients with previously untreated metastatic melanoma.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Melanoma Drug: bevacizumab
Drug: carboplatin
Drug: paclitaxel
Drug: placebo
Phase 2

Verified by Genentech August, 2008

Sponsored by: Genentech
Information provided by: Genentech
ClinicalTrials.gov identifier: NCT00434252

Study Type: Interventional

Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment

Cleveland Clinic Cancer Center
Cleveland, Ohio 44195
United States

Jai Balkissoon, M.D.., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site